Aarti Drugs opened higher at ₹414.00, compared with its previous close of ₹413.60. During today's session, the stock has traded between ₹405.05 and ₹414.05, with an average traded price of ₹408.75. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Aarti Drugs is now worth
₹ 6,564.00
resulting in a loss of
₹ 3,436.00 (34.36%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-3.55 (-0.86%)
Day High
₹414.05
Day Low
₹405.05
Day Open
₹414.00
Prev Close
₹413.60
Volume
74,623
Value Traded
₹3.05 Cr
1W Return
-1.19%
1M Return
-4.31%
3M Return
3.34%
6M Return
15.47%
1Y Return
-20.41%
Market Cap (₹ Cr.)
3,743
PE Ratio
19.80
PB Ratio
2.44
Dividend Yield
0.48%
ROE
12.58%
ROCE
12.92%
Book Value (₹)
169.70
Face Value (₹)
10.00
EPS (TTM)
5.49
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-1.19%
6 Week
-
1 Month
-4.31%
3 Month
3.34%
9 Month
6.05%
Aarti Drugs chairman Prakash Patil retires; Adhish promoted to MD
Prakash M. Patil retired as Chairman, MD, and CEO of Aarti Drugs on September 30, 2026. Adhish P. Patil was promoted from CFO to Managing Director effective October 1, 2026. Shareholders approved the leadership changes at the 41st AGM held on September 26, 2026. A new CFO will be appointed in due course to comply with SEBI regulations.
12 days agoAarti Drugs AGM approves PSOP 2026; institutions vote against plan
Aarti Drugs shareholders approved the PSOP 2026 with 84.8% votes in favor. Public institutional investors voted 99.7% against the PSOP 2026 resolution. FY26 revenue rose 7% YoY to ₹2,568 crore; Q1FY27 revenue jumped 19% YoY. All director appointments passed with over 99% shareholder support.
17 days agoAarti Drugs sets Sep 23-25 e-voting window for 41st AGM
Aarti Drugs holds its 41st AGM on September 26, 2026, via video conference. Remote e-voting is open from September 23 to September 25, 2026. The record date for voting eligibility is September 19, 2026. Newspaper advertisements were published on September 3, 2026.
1mo agoAarti Drugs approves 8 lakh performance stock option grants
Aarti Drugs board approved the Performance Stock Option Plan 2026. Up to 8,00,000 PSOs authorized for eligible employees. Options convertible into equity shares of face value ₹10 each. Final approval requires consent from company members. Trading window closed Aug 25-29 for insider trading compliance.
1mo agoAarti Drugs Q1 Results: Revenue rises 19% YoY to ₹703.6 crore
Aarti Drugs reported Q1FY27 consolidated revenue of ₹703.6 crore, up 19% YoY, driven by API price hikes and volume growth. EBITDA rose 30% to ₹96.9 crore with margins expanding to 13.8%. Net profit was ₹50.1 crore, impacted by a prior-year tax refund. Stand-alone revenue grew 20% to ₹627.6 crore, with domestic sales up 25%.
2mo agoAarti Drugs schedules investor meet with Nirmal Bang on Aug 10
Aarti Drugs Limited has announced an investor meet scheduled for August 10, 2026, at Trident BKC, Mumbai. Organized by Nirmal Bang, the session will run from 11:00 AM to 1:00 PM. The company confirmed that discussions will rely exclusively on publicly available information, in compliance with SEBI LODR regulations.
2mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Aarti Drugs is now worth
₹ 6,564.00
resulting in a loss of
₹ 3,436.00 (34.36%)
Note: Past profits do not guarantee future returns.
